{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:06:03Z","timestamp":1793412363510,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This retrospective study was to understand the clinico-epidemiologic and therapeutic aspects of pemphigus patients attending our clinic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We analyzed charts of 143 (M: F; 51:92) pemphigus patients having variable severity recorded between 2009 and 2019. Therapies were customized based on patient's age, disease severity, comorbidities, compliance prospects, and affordability. The patients were monitored monthly and as needed for therapeutic outcome in terms of disease control, reduced hospitalization, remission\/relapse, and drug toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      These patients were aged 15 to 86 years, the majority, 68 (47.5%), was 41 to 60 years of age. The pemphigus vulgaris in 83.9% patients was the commonest variant. Treatment regimens were; dexamethasone-cyclophosphamide-pulse (DCP) therapy in 51.2%, dexamethasone-azathioprine-pulse (DAP) therapy in 11%, dexamethasone-pulse (DP) therapy in 5.5%, rituximab in 24.4%, IVIg in 5.5% patients, and oral corticosteroids with or without adjuvant. Remission occurred after 2\u201317 (mean 5.8) DCP doses; 14 and 7 patients achieved remission for \u22652 y and \u22655 y, respectively. Rituximab was effective to treat both new and relapsed cases (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 31). Additional treatment with another adjuvant prolonged remission in seven patients relapsed 12\u201316 months after treatment with rituximab alone. Overall, oral corticosteroids alone and DAP therapy showed unsatisfactory response. Adverse effects seen in 41.9% of patients were mainly corticosteroids related.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The overall clinico-epidemiologic spectrum of pemphigus and therapeutic efficacy of DCP, DAP, or corticosteroids in this study was in sync with the literature. Combining rituximab and corticosteroids plus an immunomodulator initially (phase-1), followed by immunomodulator alone for one year (phase-2) will improve long-term (phase-3) therapeutic outcome. IVIg was effectively useful in patients with concurrent infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_397_21","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:02:05Z","timestamp":1646265725000},"page":"207-215","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["The Demographic Attributes, Clinical Features, and Optimal Management of 143 Patients with Pemphigus"],"prefix":"10.4103","volume":"13","author":[{"given":"Vikram K.","family":"Mahajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karaninder S.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotshna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabal","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpinder S.","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujaya","family":"Manvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket","family":"Vashist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju L.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20240828","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0190-9622(99)70145-3","article-title":"The new pemphigus variants","volume":"40","author":"Robinson","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R2-5-20240828","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jaad.2005.01.106","article-title":"Cutaneous type pemphigus vulgaris: A rare clinical phenotypes of pemphigus","volume":"52","author":"Yoshida","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R3-5-20240828","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S142471","article-title":"Emerging treatment options for the management of pemphigus vulgaris","volume":"14","author":"Kridin","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"R4-5-20240828","first-page":"185","article-title":"Cure in pemphigus: A possibility","volume":"52","author":"Pasricha","year":"1986","journal-title":"Indian J Deramtol Venereol Leprol"},{"key":"R5-5-20240828","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2133.1988.tb07104.x","article-title":"Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus","volume":"119","author":"Pasricha","year":"1988","journal-title":"Br J Dermatol"},{"key":"R6-5-20240828","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-4362.1990.tb04767.x","article-title":"Dexamethasone-cyclophosphamide pulse therapy in pemphigus","volume":"29","author":"Kaur","year":"1990","journal-title":"Int J Dermatol"},{"key":"R7-5-20240828","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1365-4362.1995.tb04430.x","article-title":"Dexamethasone cyclophosphamide pulse therapy for pemphigus","volume":"34","author":"Pasricha","year":"1995","journal-title":"Int J Dermatol"},{"key":"R8-5-20240828","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-4632.2005.02218.x","article-title":"A 12\u2013year clinico-therapeutic experience in Pemphigus: A retrospective study of 54 cases","volume":"44","author":"Mahajan","year":"2005","journal-title":"Int J Dermatol"},{"key":"R9-5-20240828","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/0019-5154.123487","article-title":"Non comparative study on various regimens (DCP, DAP and DMP) in pemphigus: Our experience","volume":"59","author":"Hassan","year":"2014","journal-title":"Indian J Dermatol"},{"key":"R10-5-20240828","first-page":"329","article-title":"Pulse therapy and its modifications in pemphigus: A six year study","volume":"69","author":"Narasimha Rao","year":"2003","journal-title":"Indian J Dermatol Venereal Leprol"},{"key":"R11-5-20240828","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"R12-5-20240828","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archderm.143.8.1033","article-title":"Treatment of severe pemphigus with rituximab: Report of 12 cases and a review of the literature","volume":"143","author":"Cianchini","year":"2007","journal-title":"Arch Dermatol"},{"key":"R13-5-20240828","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","article-title":"Adjuvant rituximab therapy of pemphigus: A single-center experience with 31 patients","volume":"148","author":"Lunardon","year":"2012","journal-title":"Arch Dermatol"},{"key":"R14-5-20240828","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): A prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"R15-5-20240828","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/ijd.14546","article-title":"Rituximab as an adjuvant therapy for pemphigus: Experience in 61 patients from a single centre with long-term follow-up","volume":"59","author":"Sharma","year":"2020","journal-title":"Int J Dermatol"},{"key":"R16-5-20240828","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: Recommendations by an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R17-5-20240828","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4103\/0378-6323.102354","article-title":"Rituximab in pemphigus","volume":"78","author":"Kanwar","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R18-5-20240828","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0378-6323.174379","article-title":"Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study","volume":"82","author":"Sharma","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R19-5-20240828","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R20-5-20240828","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-4632.2004.02501.x","article-title":"Pemphigus: Analysis of 1209 cases","volume":"44","author":"Chams-Davatchi","year":"2005","journal-title":"Int J Dermatol"},{"key":"R21-5-20240828","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1468-3083.2011.04362.x","article-title":"The course and prognosis of pemphigus in 47 Tunisian patients","volume":"27","author":"Khaled","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R22-5-20240828","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4103\/ijdvl.IJDVL_323_17","article-title":"Clinical, immunological profile and follow-up of patients with pemphigus: A study from India","volume":"84","author":"Ramassamy","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R23-5-20240828","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/archderm.1973.01620180083027","article-title":"Pemphigus vulgaris in 3\u00bdyear-old baby","volume":"107","author":"Berger","year":"1973","journal-title":"Arch Dermatol"},{"key":"R24-5-20240828","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/1523-1747.ep12612836","article-title":"Comparative epidemiology of pemphigus in Tunisia and France: Unusual incidence of pemphigus foliaceus in young Tunisian women","volume":"104","author":"Bastuji-Garin","year":"1995","journal-title":"J Invest Dermatol"},{"key":"R25-5-20240828","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/archderm.1996.03890360021005","article-title":"Treatment of pemphigus vulgaris with brief high dose intravenous glucocorticoids","volume":"132","author":"Werth","year":"1996","journal-title":"Arch Dermatol"},{"key":"R26-5-20240828","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-4362.1990.tb04765.x","article-title":"Pemphigus therapy with oral prednisolone regimens","volume":"9","author":"Ratnam","year":"1990","journal-title":"Int J Dermatol"},{"key":"R27-5-20240828","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/11311150-000000000-00000","article-title":"Dexamethasone-cyclophosphamide pulse therapy in pemphigus: A review of 72 cases","volume":"11","author":"Zivanovic","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"R28-5-20240828","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4103\/0378-6323.136832","article-title":"Intermittent doses of rituximab used as adjuvant therapy in refractory pemphigus","volume":"80","author":"Londhe","year":"2014","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R29-5-20240828","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2011.12.019","article-title":"Rituximab treatment of severe pemphigus: Long-term results including immunologic follow-up","volume":"67","author":"Reguiai","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R30-5-20240828","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jdv.12080","article-title":"Clinical experience of different schedules of rituximab in pemphigus with various disease severities","volume":"28","author":"Cho","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_397_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:11:38Z","timestamp":1787166698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_397_21"}},"subtitle":["A Retrospective Observational Study from a Tertiary Care Center of India"],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_397_21","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}